Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3537021 for Chemotherapy-Induced Nausea and Vomiting in Adults With Malignant Tumors
CTR20255160Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing LY3537021 with Placebo (2 arms). Primary endpoint: Proportion of subjects with complete response (CR) in delayed phase CINV. Started Jan 2026; status: active.
02
Drugs
LY3537021
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on CTR20255160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255160.